Q-omics provides the consensus-scored INO80C profile across patient tissues and cancer cell-line models. INO80C expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, INO80C is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, INO80C RNA expression shows 19,595 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where INO80C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INO80C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INO80C survival associations across molecular data types. INO80C RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INO80C RNA expression–survival associations across cancer types. High INO80C expression shows unfavorable associations in ACC, LUAD, UVM and LIHC, but favorable associations in THCA and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for INO80C RNA expression.
This table summarizes INO80C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for INO80C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INO80C shows lower tumor expression in KICH, LUAD and COAD and higher tumor expression in KIRC, LIHC and BLCA. The KIRC box plot shows higher INO80C RNA expression in tumor versus normal tissue (log2 FC = +1.252, t-test p < 0.001).
This table shows molecular features associated with INO80C in patient tissues and cancer cell lines. In patient samples, INO80C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, INO80C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
